Han Zheng

Ms. Han Zheng

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2023 in International Journal of Surgery
Verified
Journal Article
Open access
SJShitao Jiang
Shitao Jiang
YLYaoge Liu
Yaoge Liu
HZHan Zheng
Han Zheng
LZLei Zhang
Lei Zhang
HZHaitao Zhao
Haitao Zhao
XLXin Lu
Xin Lu
Research has shown that neoadjuvant immunotherapy may provide more significant clinical benefits to cancer patients undergoing surgery than adjuvant therapy. This study examines the development of neoadjuvant immunotherapy research using bibliometric analysis. As of 12 February 2023, articles on neoadjuvant immunotherapy in the Web of Science Core Collection were collected. Co-authorship and keyword co-occurrence analyses and visualizations were performed using VOSviewer, while CiteSpace was used to identify bursting keywords and references. The study analyzed a total of 1222 neoadjuvant immunotherapy publications. The top contributors to this field were the United States, China, and Italy, and the journal with the most publications was Frontiers in Oncology. Francesco Montorsi had the highest H-index. The most common keywords were ‘immunotherapy’ and ‘neoadjuvant therapy’. The study conducted a bibliometric analysis of over 20 years of neoadjuvant immunotherapy research, identifying the countries, institutions, authors, journals, and publications involved in this field. The findings provide a comprehensive overview of neoadjuvant immunotherapy research.

4 January 2024 in International Journal of Surgery
Verified
Journal Article
Open access
LZLei Zhang
Lei Zhang
HZHan Zheng
Han Zheng
SJShi-Tao Jiang
Shi-Tao Jiang
YLYao-Ge Liu
Yao-Ge Liu
TZTing Zhang
Ting Zhang
YXYiyao Xu
Yiyao Xu
Various immunotherapy has been greatly applied to comprehensive treatment of malignant cancer under different degrees of tumor burden. Scientific researchers have gained considerable progress in the relationship between immunotherapy and tumor burden in recent years. This review aimed to explore the prospect and developing trends in the field of tumor burden and immunotherapy from a bibliometric perspective. Articles about tumor burden and immunotherapy were collected from the Web of Science Core Collection (WoSCC) (retrieved on 3 January 2023). The R package ‘Bibliometrix’ analyzed the primary bibliometric features and created a three-filed plot to display the relationship between institutions, countries, and keywords. VOSviewer was used for co-authorship analysis, co-occurrence analysis, and their visualization. And CiteSpace calculated the citation burst references and keywords. A total of 1030 publications were retrieved from 35 years of scientific researches. The United States (US) and China published the most articles. The most productive journals were Cancer Immunology Immunotherapy and Journal for ImmunoTherapy of Cancer. The top one institution of the highest output was University of Texas MD Anderson Cancer Center. The hot keywords of strong citation burst strength in recent years were ‘nivolumab’, ‘tumor microenvironment’, and ‘immune checkpoint inhibitor’. The most popular tumor type is melanoma. This bibliometric analysis mapped a basic knowledge structure. The field of tumor burden and immunotherapy is entering a rapid growing stage and keeping it value for future research.

10 July 2023 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
YLYao-Ge Liu
Yao-Ge Liu
SJShi-Tao Jiang
Shi-Tao Jiang
LZLei Zhang
Lei Zhang
HZHan Zheng
Han Zheng
TZTing Zhang
Ting Zhang
XLXin Lu
Xin Lu
Background: As the complexity and diversity of the tumor immune microenvironment (TIME) are becoming better understood, burgeoning research has progressed in this field. However, there is a scarcity of literature specifically focused on the bibliometric analysis of this topic. This study sought to investigate the development pattern of TIME-related research from 2006 to September 14, 2022, from a bibliometric perspective. Methods: We acquired both articles and reviews related to TIME from the Web of Science Core Collection (WoSCC) (retrieved on September 14, 2022). R package “Bibliometrix” was used to calculate the basic bibliometric features, present the collaborative conditions of countries and authors, and generate a three-field plot to show the relationships among authors, affiliations, and keywords. VOSviewer was utilized for co-authorship analysis of country and institution and keyword co-occurrence analysis. CiteSpace was used for citation burst analysis of keywords and cited references. In addition, Microsoft Office Excel 2019 was used to develop an exponential model to fit the cumulative publication numbers. Results: A total of 2545 publications on TIME were included, and the annual publication trend exhibited a significant increase over time. China and Fudan University were the most productive country and institution, with the highest number of publications of 1495 and 396, respectively. Frontiers in Oncology held the highest number of publications. A number of authors were recognized as the main contributors in this field. The clustering analysis revealed six clusters of keywords that highlighted the research hot spots in the fields of basic medical research, immunotherapy, and various cancer types separately. Conclusions: This research analyzed 16 years of TIME-related research and sketched out a basic knowledge framework that includes publications, countries, journals, authors, institutions, and keywords. The finding revealed that the current research hot spots of the TIME domain lie in “TIME and cancer prognosis”, “cancer immunotherapy”, and “immune checkpoint”. Our researchers identified the following areas: “immune checkpoint-based immunotherapy”, “precise immunotherapy” and “immunocyte pattern”, which may emerge as frontiers and focal points in the upcoming years, offering valuable avenues for further exploration.

29 December 2025 in Research Square
Verified
Preprint
Open access
PDF file
ZCZhihong Chen
Zhihong Chen
HZHan Zheng
Han Zheng
YMYunhan Mao
Yunhan Mao
SZShunan Zhou
Shunan Zhou
SZShenao Zhang
Shenao Zhang
XLXin Lu
Xin Lu
Background: Early-onset liver cancer (EOLC), occurring in individuals aged 15-49, is an emerging global health challenge. This study aims to assess health inequalities in EOLC burden across regions and sexes and to inform targeted interventions. Methods: Using Global Burden of Disease (GBD) 2021 data, we analyzed global EOLC incidence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021. Analyses included Joinpoint regression, decomposition, locally estimated scatterplot smoothing (LOESS), and frontier efficiency assessment. Trends to 2050 were projected via a gender-stratified Bayesian age-period-cohort (BAPC) model. Results: Absolute EOLC burden increased globally, though age-standardized rates (ASRs) declined overall. Notably, age-standardized incidence rates (ASIRs) rose among women in high socio-demographic index (SDI) regions and among men in low-middle SDI regions. Hepatitis B virus (HBV) remained the leading cause, but alcohol, hepatitis C virus (HCV), and nonalcoholic steatohepatitis (NASH), especially in young women, showed increasing contributions. Population growth and aging drove increases in the absolute burden. Frontier analysis identified Mongolia as the lowest-performing country, while Somalia, Burundi, and Ethiopia achieved relatively efficient control. The BAPC model projects continued ASR declines by 2050, yet female ASIR is expected to rise modestly due to rising NASH. Conclusion: Despite an overall declining EOLC burden, persistent gender and regional inequities and the growing impact of metabolic risks like NASH call for precision public health approaches, including etiology-specific strategies, early screening for high-risk groups (particularly young women), and strengthened health systems in underperforming regions.